Medical device and MedTech insights, news, tips and more

Critical Innovations Receives Breakthrough Device Designation for FOAM Device

July 3, 2019

criticalinnovationslogo

Critical Innovations announced earlier this week that the FDA has granted breakthrough device designation for its “Fast Onset Abdominal Management™ (F.O.A.M.™) device, which is designed to deliver a quickly-expanding foam to tamponade severe internal bleeding in trauma patients. F.O.A.M.™ research and development is supported by funding from U.S. Army Medical Materiel Development Activity (USAMMDA), through the Medical Technology Enterprise Consortium (MTEC), under a contract worth over one million dollars.

F.O.A.M.™ is designed to control severe intra-abdominal bleeding in critically ill trauma patients, when surgical intervention is not immediately available. Once delivered into the body via a specialized auto-stopping needle, its foaming agent expands and exerts pressure. Its main polymer component is unusual in that it exhibits reverse-phase-shift properties, meaning it becomes more solid at warmer temperatures (e.g. body temperature). If a subsequent surgical procedure is required, a surgeon can reverse the process and wash it away with cooled liquid. However, if no further procedure is required, the foaming agent should gradually dissolve to be removed by the body.

“The goal of the F.O.A.M.™ device is to provide a lifesaving bridge to surgical care for patients who might otherwise die from their injuries,” said Dr. Ross Donaldson, President & CEO of Critical Innovations and an emergency physician at one of Los Angeles’ main trauma centers. “In such patients, the probability of death increases approximately 1% for each 3-minute delay to surgery, meaning each minute counts.” Dr. Donaldson has been widely recognized for spearheading the development of emergency and trauma systems in Iraq and other countries in conflict, where he saw numerous such injuries.

“Military funding of F.O.A.M.™ device development has been key to our success so far,” stated Dr. Donaldson. To date, the company has developed a proof-of-concept device and performed initial animal testing. “We look forward to engaging with the FDA through the Breakthrough Devices Program.” The program helps speed up the development process through expedited regulatory assessment and review of medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions.

See Full Press Release at the Source: U.S. FDA grants Critical Innovations breakthrough device designation for its F.O.A.M.™ device


Press Release by Critical Innovations


A Speciality Recruiting Firm Exclusively Servicing The Medical Device Industry

Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.